AbbVie (NYSE: ABBV) has announced late-stage results for its JAK inhibitor Rinvoq (upadacitinib) in the treatment of moderate-to-severe atopic dermatitis, a skin condition characterized by inflammation and itching. The data, released this week, highlights the drug’s performance over an extended period of two years.
Sustained Efficacy in Atopic Dermatitis
The primary and secondary endpoints of the study, which focused on skin clearance and itch reduction at week 16, were successfully met. Notably, the clinical benefits of Rinvoq were observed to continue through week 140, indicating a sustained efficacy in managing the symptoms of atopic dermatitis.
Phase IIb Study in Non-Segmental Vitiligo (NSV)
AbbVie also provided updates on a Phase IIb study for Rinvoq in non-segmental vitiligo (NSV), a condition where the skin loses its pigment in patches. The trial successfully met its primary and secondary endpoints, showing a significant reduction in facial and body vitiligo area compared to placebo. Re-pigmentation rates continued to improve between weeks 24 and 52. Based on these positive results, AbbVie will progress Rinvoq into Phase III trials for NSV.
Future Outlook
The advancement of Rinvoq to Phase III trials in NSV, along with the sustained efficacy demonstrated in atopic dermatitis, underscores AbbVie’s commitment to expanding the therapeutic potential of Rinvoq. These late-stage results are promising for patients suffering from these conditions and highlight Rinvoq’s potential as a treatment option in dermatology.-Fineline Info & Tech
